Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06467955 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MagDI Canada Study

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Feb 2026 to Jan 27, 2026
    • Study completion date: Dec 2026 to Nov 2026
    • Site details revised at 3 of 3 sites
    v6
  2. Primary completion date: Dec 2025 to Feb 2026
    • Study completion date: Feb 2027 to Dec 2026
    v5
  3. Primary completion date: Oct 2025 to Dec 2025
    • Study completion date: Dec 2026 to Feb 2027
    v4
  4. Primary completion date: Mar 2026 to Oct 2025
    • Study completion date: May 2026 to Dec 2026
    v3
  5. Primary completion date: Aug 31, 2025 to Mar 2026
    • Study completion date: Aug 31, 2025 to May 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GT Metabolic Solutions, Inc.
11 trials monitored
See 1 trial at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The objective of the MagDI Canada study is to evaluate the performance and safety of the MagDI System in eligible participants who are indicated for a duodeno-ileal (small bowel) side-to-side anastomosis procedure for partial intestinal diversion as one example of a small bowel clinical procedure requiring a side-to-side anastomosis. The secondary objective includes initial efficacy of the duodeno-ileal diversion using the MagDI System.
Trial Details
NCT Number NCT06467955
Lead Sponsor GT Metabolic Solutions, Inc.
Conditions
(from sponsor)		 Obesity, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2, Obesity
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov